FDA AI Guidance for Medical Devices

Preparing an FDA submission requires more than assembling technical documentation. Manufacturers must demonstrate that their quality processes support the design, development, testing, and ongoing management of a medical device. As submission teams begin collecting supporting evidence, they often discover weaknesses in their quality system that were not apparent during day-to-day operations.

The discussion around eQMS vs QMS is not simply about replacing paper records with electronic tools. It is about determining whether a quality system can consistently produce the documentation, traceability, and objective evidence FDA reviewers expect. Whether preparing an initial submission or updating an existing product, a mature quality system plays a significant role in regulatory success.

Why Quality System Gaps Become a Problem During FDA Submissions

Many quality system issues do not become obvious until regulatory teams begin assembling submission documentation. Records that seemed easy to manage internally may be difficult to locate, incomplete, or inconsistent when they are needed to support design decisions, testing activities, or risk management.

FDA reviewers rely on the evidence required for the applicable submission type to evaluate the device's safety, effectiveness, or substantial equivalence. Missing documentation or inconsistent records can delay submission preparation and generate additional questions during review.

Common Documentation Challenges

Manufacturers frequently encounter issues like:

• Missing or outdated procedures
• Incomplete design history documentation
• Inconsistent document approvals
• Weak traceability between requirements, risks, and testing
• Training records stored in multiple systems
• Difficulty locating evidence that supports product claims

These challenges often require quality and regulatory teams to spend valuable time reconstructing documentation rather than preparing the submission itself.

Organizations with mature medical device regulatory compliance⁠ processes are generally better positioned because documentation has been maintained throughout development instead of assembled at the last minute.

For companies preparing an FDA submission for the first time, working with experienced professionals that provide FDA 510(k) submission support⁠ can also help identify documentation gaps before they affect review timelines.

eQMS vs QMS: Which Is Better for Managing Submission Documentation?

Medical device manufacturers subject to FDA's Quality Management System Regulation must establish and maintain an applicable quality management system, but the way quality records are managed can vary considerably. Some organizations continue using paper files, spreadsheets, shared drives, or multiple disconnected applications, while others use an electronic Quality Management System (eQMS) to centralize quality activities.

During routine operations, both approaches may appear effective. During FDA submission preparation, however, differences in document control, traceability, and record retrieval often become much more apparent.

Traditional Quality System Challenges

Traditional quality systems frequently depend on manual processes for document approvals, version control, and record storage. As organizations grow, these processes become increasingly difficult to manage.

Common challenges include:

• Multiple versions of controlled documents
• Manual approval workflows
• Records stored across several locations
• Limited visibility into document revisions
• Training records maintained separately from procedures
• Time-consuming document retrieval during submission preparation

These issues can make it more difficult to demonstrate that quality activities were completed consistently throughout product development.

How an eQMS Improves Documentation Management

An eQMS provides a centralized platform for managing controlled documents, training records, CAPAs, complaint investigations, audit findings, and quality records throughout the product lifecycle.

Rather than searching through multiple systems, quality and regulatory teams can retrieve supporting documentation from a single location. This improves consistency while making it easier to prepare submission-ready documentation.

An eQMS also helps support:

• Centralized document control
• Automated approval workflows
• Electronic audit trails
• Integrated training management
• Improved CAPA management
• Better visibility into document revisions and approval history

While implementing an eQMS does not guarantee regulatory success, it can simplify documentation management and improve accessibility during submission preparation.

Why Traceability Matters

Depending on the device and submission type, FDA reviewers may evaluate how submitted requirements, risk management activities, verification testing, and design changes relate to one another. Maintaining these relationships manually becomes increasingly difficult as documentation grows.

Electronic quality systems help preserve these connections while making it easier to retrieve supporting evidence during FDA review.

Organizations planning 510(k) submission preparation⁠ often discover that improving document control and traceability before submission reduces unnecessary delays and strengthens the overall submission package.

Common Quality System Issues That Delay FDA Reviews

FDA reviewers evaluate whether the submitted documentation satisfies the requirements for the applicable premarket submission and supports the device's safety, effectiveness, or substantial equivalence. When supporting records are incomplete or difficult to retrieve, reviewers may request additional information before continuing their evaluation.

Incomplete or unclear submission documentation can lead to requests for additional information and extend the review timeline.

Some of the most common issues include:

• Missing or outdated procedures. Controlled procedures should reflect current practices and align with the documentation included in the submission.
• Incomplete training records. Manufacturers should be able to demonstrate that personnel were trained on applicable procedures before performing regulated activities.
• Poor design control documentation. Design inputs, outputs, reviews, verification, validation, and design changes should clearly support the overall development history of the device.
• Weak traceability. Depending on the submission requirements, unclear connections between requirements, risks, testing, and validation activities may make the submitted evidence more difficult to evaluate.
• Inconsistent CAPA documentation. Corrective and preventive action records should demonstrate how quality issues were investigated, resolved, and monitored.
• Difficulty demonstrating process controls. Manufacturers should be able to provide objective evidence showing that documented quality processes were consistently followed.

Performing a documentation review before submission helps identify these issues while there is still time to address them. Companies developing software-enabled products should also ensure their quality processes align with broader healthtech regulatory compliance⁠ expectations as regulatory requirements continue to evolve.

How an eQMS Can Improve Submission Readiness

An eQMS supports more than routine quality activities. It helps manufacturers organize documentation, maintain traceability, and retrieve supporting evidence more efficiently during FDA submissions, audits, and inspections.

Rather than relying on disconnected records or manual processes, an eQMS provides a centralized approach to managing quality documentation throughout the product lifecycle.

Key benefits include:

• Centralized document control. Controlled procedures, forms, work instructions, and quality records are maintained in one location, reducing the risk of duplicate or outdated documents.
• Automated approval workflows. Electronic routing helps ensure documents are reviewed, approved, and version controlled before release.
• Electronic training management. Training records can be linked directly to controlled documents, making it easier to demonstrate that employees were trained on current procedures.
• Improved traceability. Requirements, design controls, risk management activities, CAPAs, and verification records remain connected throughout development.
• Integrated CAPA and complaint management. Electronic workflows improve visibility into investigations, corrective actions, approvals, and effectiveness checks.
• Faster retrieval of supporting evidence. Centralized records can simplify responses to applicable FDA requests and help prepare organizations for audits and inspections.

An eQMS can also support broader compliance initiatives by creating documentation that is easier to review, maintain, and update throughout the product lifecycle.

Evaluating Whether Your Current Quality System Is Submission-Ready

Before beginning an FDA submission, manufacturers should evaluate whether their quality system can consistently produce the records needed to support regulatory review. Waiting until submission assembly often reveals documentation gaps that are more difficult to address under tight timelines.

A structured assessment should include questions such as:

• Are document control procedures consistently followed?
• Can requirements, risks, testing, and design controls be traced from development through validation?
• Are training records complete, current, and readily available?
• Are CAPAs documented, investigated, and closed appropriately?
• Can supporting records be retrieved quickly if FDA requests additional information?

A quality system assessment helps identify compliance risks before they affect submission timelines. It also provides an opportunity to improve documentation consistency and strengthen overall submission readiness.

Organizations with increasingly complex products or software development activities often benefit from periodic reviews of their quality processes alongside their regulatory strategy.

When Companies Typically Transition to an eQMS

There is no single point at which every manufacturer should implement an eQMS. However, several business milestones commonly prompt organizations to evaluate whether manual quality processes remain effective.

Companies often consider transitioning when they are:

• Preparing their first FDA submission
• Expanding a medical device product portfolio
• Growing engineering, quality, and regulatory teams
• Entering new regulatory markets
• Developing more complex software-enabled medical devices
• Managing larger volumes of controlled quality records
• Preparing for FDA inspections or third-party audits

As software complexity increases, manufacturers should also ensure that supporting technical documentation keeps pace with evolving regulatory expectations. Organizations developing AI-enabled products may require specialized AI/ML submission documentation⁠, while connected devices often require comprehensive cybersecurity documentation for FDA submissions⁠ as part of the overall submission package.

Building a Quality System That Supports Long-Term Regulatory Success

Submission readiness begins long before documentation is assembled for FDA review. Manufacturers that invest in consistent quality processes throughout product development are often better positioned to respond to regulatory questions, support audits, and prepare future submissions with greater efficiency.

Whether an organization maintains a traditional quality management system or implements an eQMS, the objective remains the same: establish quality processes that support complete documentation, effective design controls, strong traceability, and continuous improvement.

As products, teams, and regulatory responsibilities grow, quality systems should evolve as well. Regular assessments, documentation reviews, and process improvements can help reduce compliance risks while supporting long-term regulatory success.

Quality Commercial Consultants provides medical device consulting services⁠ to help manufacturers strengthen quality documentation, improve submission readiness, and navigate evolving regulatory expectations. If you have questions about FDA submissions or quality system requirements, explore our medical device regulatory FAQs⁠ for additional guidance.

To learn more about our collaborative approach, visit how we work⁠. If you're evaluating whether your current quality system can support an upcoming FDA submission, contact us⁠ to discuss how Quality Commercial Consultants can help you strengthen your documentation and regulatory strategy.